GILD

#78
Gilead Sciences Inc
140.75 USD
+1.24%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
140.04
140.81
Годовой диапазон
95.29
157.27
Дневное изменение
+1.24%
Месячное изменение
-2.41%
6-месячное изменение
+19.20%
Годовое изменение
+32.28%
Предыдущее закрытие
139.03
Открыть
140.33
Bid
Ask
Минимум
140.04
High
140.81
Объем
424
Открыть полный график

Financials

Обзор Отчетность Статистика Дивиденды
Квартал Год
  • Market Capitalization 174.73 B
  • Employee 17 K
  • Founded 1987
  • CEO Daniel O'Day
  • Website www.gilead.com
  • Headquarter Delaware, United States
  • FIGI BBG000CKGBP2
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
18.1
Коэффициент цена/денежный поток
5.23
Дивиденды на акцию
3.16
Дивидендная доходность, %
2.57

Gilead Sciences Inc

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. However, it came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world.

Новости